B-Adrenergic Receptor Blockers (Expert Consensus Document on)

ESC Clinical Practice Guidelines

Topic(s):

Hypertension

Heart Failure: Treatment

Cardiovascular Pharmacology and Pharmacotherapy

Guidelines version available to download

Full text

Published in 2004

Reference European Heart Journal (2004) 25, 1341–1362; 10.1016/j.ehj.2004.06.002

Endorsed by cardiac societies

Table of contents: Full Text (ESC Clinical Practice Guidelines)

Pharmacology

Definition
Classification of b-blockers
Pharmacokinetic properties: Lipophilic drugs, Hydrophilic drugs, Balanced clearance drugs
Mechanism of action
Adverse events: Cardiovascular, Metabolic, Pulmonary, Central effects, Sexual dysfunction
Contraindications
Drug interactions
Dosing of b-blockers

Clinical efficacy and use

Acute myocardial infarction (AMI)
Secondary prevention after myocardial infarction
Non-ST-segment elevation acute coronary syndromes
Chronic, stable ischaemic heart disease
Heart failure: Heart failure and preserved systolic function, Acute heart failure
Arrhythmias: Sinus tachycardia, Supraventricular tachycardias, Tachycardias in WPW syndrome, Atrial flutter, Atrial fibrillation, Ventricular arrhythmias
Prevention of sudden cardiac death: Acute myocardial infarction, Heart failure, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Mitral valve prolapse, Myocardial bridging, Long QT syndrome (LQTS), Catecholaminergic polymorphic ventricular tachycardia, SCD in the normal heart, Other situations

Hypertension

Aortic dissection

Hypertrophic cardiomyopathy

Prophylactic use in non-cardiac surgery

Vasovagal syncope

b-Blockers during pregnancy